Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This phase 3 trial tests a lab-made clotting factor VIII in 60 people with severe hemophilia A. The treatment is given on-demand for new bleeding episodes or before surgery. The goal is to see if it safely and effectively stops bleeding and supports surgical recovery.

This phase 2 trial tests TQC2938, a lab-made antibody, in 256 people with moderate to severe COPD. The goal is to see if the drug can reduce the number of serious flare-ups over 24 weeks compared to a placebo. Participants receive injections and are monitored for safety and side …